Royalty Pharma plc - Class A Ordinary Shares (RPRX) Covered Calls

Royalty Pharma plc is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry. The company acquires revenue interests in many of the world’s best-selling drugs, providing non-dilutive capital to academic institutions and biotech firms. By collecting top-line, sales-based payments on a diversified portfolio of approved therapies, the firm offers investors a high-margin vehicle for capturing pharmaceutical growth.

You can sell covered calls on Royalty Pharma plc - Class A Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RPRX (prices last updated Wed 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Royalty Pharma plc (RPRX) operates as a specialized investment firm that serves as a vital engine for the biopharmaceutical ecosystem. The company does not conduct its own clinical trials or manufacturing; instead, it acquires royalties on approved and development-stage therapies. By providing upfront cash to original innovators—ranging from university labs to global pharmaceutical giants—Royalty Pharma enables these entities to recycle capital into new research. In exchange, Royalty Pharma receives a percentage of the top-line sales of the resulting products, creating a highly diversified and high-margin cash flow stream.

The company’s portfolio includes royalties on over 35 commercial products, including industry leaders like the Vertex cystic fibrosis franchise, GSK’s Trelegy, and Johnson & Johnson’s Tremfya. A key component of the current strategy is the expansion into "synthetic royalties," where Royalty Pharma creates new royalty streams by funding late-stage clinical trials or product launches directly. This innovative financing model has become increasingly popular as traditional equity markets for biotech fluctuate, allowing RPRX to deploy significant capital annually into best-in-class therapies addressing significant unmet medical needs.

Competitive Landscape

Royalty Pharma occupies a dominant position in the royalty acquisition space, often operating with a scale that smaller private players cannot match. Its most frequent points of comparison are large-cap pharmaceutical companies like AbbVie and Pfizer, which also manage large portfolios of patented drugs. However, unlike these firms, RPRX carries no direct research and development (R&D) or manufacturing risk.

In the financial and specialized healthcare space, it is often compared to firms like SPDR S&P Biotech ETF for general sector exposure or Bristol-Myers Squibb for its income profile. Because Royalty Pharma generates predictable, patent-protected cash flows, it is a staple for income-oriented investors. The stock maintains a liquid options market that is frequently used for covered call writing, particularly by investors looking to capture yield from a portfolio that is less volatile than a pure-play biotech stock.

Strategic Outlook and Innovation

The strategic future of Royalty Pharma is defined by its 2026 push into the Asian markets and its focus on emerging therapeutic areas like GLP-1 weight-loss treatments and neuroscience. Following the internalization of its external manager in 2025, the company has significantly improved its governance and reduced its operating costs, allowing a higher percentage of royalty receipts to flow directly to shareholders. The company is currently targeting a steady compound annual growth rate for its portfolio receipts through the end of the decade, supported by a robust pipeline of "blockbuster" potential therapies currently in Phase 3 trials.

Innovation at Royalty Pharma involves the use of deep-science due diligence and proprietary data analytics to identify winners early in the development cycle. By securing royalties on therapies like those for lupus and cardiovascular disease years before they reach the market, the company builds long-term value. Additionally, the firm’s entry into China in early 2026 marks a major milestone in globalizing its platform, ensuring that Royalty Pharma can capture the next wave of global medical breakthroughs while maintaining a fortress balance sheet and a growing dividend policy.

Want more examples? RPM Covered Calls | RPV Covered Calls